Jaktinib Dihydrochloride Monohydrate is a potent inhibitor of JAK1 and JAK2 that demonstrated efficacy and safty in preclinical study and safty in a phase 1 in healthy volunteerThis phase IIB, open-label, multicenter study evaluated the efficacy and safety of oral Jaktinib Dihydrochloride in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With Ruxolitinib

